Copeland Capital Management LLC Sells 361,253 Shares of Perrigo Company plc $PRGO

Copeland Capital Management LLC reduced its holdings in Perrigo Company plc (NYSE:PRGO) by 16.1% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,889,204 shares of the company’s stock after selling 361,253 shares during the quarter. Copeland Capital Management LLC owned 1.37% of Perrigo worth $42,073,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of PRGO. Geneos Wealth Management Inc. grew its holdings in shares of Perrigo by 439.1% during the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after purchasing an additional 786 shares in the last quarter. Huntington National Bank lifted its position in Perrigo by 237.8% during the second quarter. Huntington National Bank now owns 1,054 shares of the company’s stock valued at $28,000 after purchasing an additional 742 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its stake in Perrigo by 54.6% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,201 shares of the company’s stock worth $32,000 after buying an additional 424 shares in the last quarter. Hantz Financial Services Inc. increased its holdings in shares of Perrigo by 101.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 1,234 shares of the company’s stock worth $33,000 after buying an additional 620 shares during the last quarter. Finally, Kestra Investment Management LLC raised its position in shares of Perrigo by 57.1% during the 2nd quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock valued at $47,000 after buying an additional 642 shares in the last quarter. Institutional investors own 95.91% of the company’s stock.

Insider Transactions at Perrigo

In other news, Director Geoffrey M. Parker acquired 7,500 shares of the firm’s stock in a transaction on Wednesday, November 12th. The shares were purchased at an average price of $14.18 per share, for a total transaction of $106,350.00. Following the completion of the transaction, the director owned 17,375 shares of the company’s stock, valued at $246,377.50. The trade was a 75.95% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. JPMorgan Chase & Co. cut their target price on shares of Perrigo from $20.00 to $18.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Perrigo in a report on Monday, December 22nd. Zacks Research lowered Perrigo from a “hold” rating to a “strong sell” rating in a research report on Friday, November 7th. Wall Street Zen downgraded Perrigo from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Jefferies Financial Group cut their target price on Perrigo from $27.00 to $23.00 and set a “hold” rating for the company in a research note on Monday, October 27th. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average target price of $22.00.

Perrigo Trading Up 0.6%

NYSE PRGO opened at $13.91 on Tuesday. The firm has a market cap of $1.91 billion, a PE ratio of -36.59 and a beta of 0.39. Perrigo Company plc has a 1-year low of $12.17 and a 1-year high of $30.93. The stock has a 50-day moving average of $15.24 and a 200-day moving average of $21.13. The company has a current ratio of 2.51, a quick ratio of 1.44 and a debt-to-equity ratio of 0.81.

Perrigo (NYSE:PRGO) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.05. The business had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $1.10 billion. Perrigo had a positive return on equity of 9.16% and a negative net margin of 1.21%.The business’s quarterly revenue was down 4.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.81 EPS. Perrigo has set its FY 2025 guidance at 2.700-2.80 EPS. As a group, sell-side analysts forecast that Perrigo Company plc will post 2.56 EPS for the current year.

Perrigo Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 16th. Shareholders of record on Friday, November 28th were given a dividend of $0.29 per share. The ex-dividend date of this dividend was Friday, November 28th. This represents a $1.16 annualized dividend and a yield of 8.3%. Perrigo’s dividend payout ratio is presently -305.26%.

Perrigo Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.